These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 18330697

  • 1. Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.
    Søiland H, Janssen EA, Kørner H, Varhaug JE, Skaland I, Gudlaugsson E, Baak JP, Søreide JA.
    Breast Cancer Res Treat; 2009 Feb; 113(3):519-28. PubMed ID: 18330697
    [Abstract] [Full Text] [Related]

  • 2. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Feb; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 4. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T.
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 10. Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact.
    Casalini P, Carcangiu ML, Tammi R, Auvinen P, Kosma VM, Valagussa P, Greco M, Balsari A, Ménard S, Tagliabue E.
    Clin Cancer Res; 2008 Jan 01; 14(1):25-31. PubMed ID: 18172248
    [Abstract] [Full Text] [Related]

  • 11. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.
    BMC Cancer; 2008 Oct 23; 8():307. PubMed ID: 18947390
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
    Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.
    Cancer; 2009 Nov 01; 115(21):4917-23. PubMed ID: 19691094
    [Abstract] [Full Text] [Related]

  • 14. Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia.
    Serra Díaz C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Baltasar A, Medrano J.
    Br J Surg; 1999 Sep 01; 86(9):1190-7. PubMed ID: 10504376
    [Abstract] [Full Text] [Related]

  • 15. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y, Xu BH, Li Q, Zhang P, Zhao LM, Yuan P, Wang JY.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 08; 88(2):77-81. PubMed ID: 18353207
    [Abstract] [Full Text] [Related]

  • 16. Prognostic relevance of cyclin E expression in operable breast cancer.
    Potemski P, Kusińska R, Pasz-Walczak G, Piekarski JH, Watała C, Płuciennik E, Bednarek AK, Kordek R.
    Med Sci Monit; 2009 Feb 08; 15(2):MT34-40. PubMed ID: 19179977
    [Abstract] [Full Text] [Related]

  • 17. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.
    Clin Cancer Res; 2009 May 15; 15(10):3610-6. PubMed ID: 19401349
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.